Research

In a divided two-day meeting, the Pharmacy Compounding Advisory Committee supported BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, while rejecting Emideltide. The votes do not approve the peptides or immediately authorize their use in patient-specific pharmacy compounding.

A result can be statistically significant and still barely matter — or matter enormously and just miss significance. Learning to tell the difference is one of the most useful skills for reading research well.

The path from a promising finding in the lab to a proven human therapy is long by design. Understanding why makes you a sharper — and more patient — reader of early science.

In a single day, the FDA told multiple peptide sellers that an RUO label does not control when the surrounding evidence establishes an intended human-drug use. The reasoning is worth reading closely.